136117-93-6

Usage

Uses

Used in Cancer Research:
8-Bromo-6-methylimidazo[1,2-a]pyridine is utilized as a mutagen and tumor inducer in animal models for cancer research. It serves as a valuable tool for understanding the mechanisms of carcinogenesis and the effects of mutagens on DNA, which can help in the development of strategies to prevent or treat cancer.
Used in Food Safety and Nutrition Studies:
8-Bromo-6-methylimidazo[1,2-a]pyridine is used as a marker for the presence of heterocyclic amines in cooked meat products. It aids researchers in studying the impact of cooking methods and conditions on the formation of potentially harmful compounds in food, thereby contributing to the improvement of food safety and nutrition guidelines.
Used in Public Health and Epidemiological Studies:
8-Bromo-6-methylimidazo[1,2-a]pyridine is employed in epidemiological studies to investigate the correlation between the consumption of cooked meat and the risk of developing certain types of cancer. This helps public health officials and policymakers to assess the risks associated with dietary habits and to develop recommendations for reducing exposure to potential carcinogens in the diet.

InChI:InChI=1/C8H7BrN2/c1-6-4-7(9)8-10-2-3-11(8)5-6/h2-5H,1H3

Upstream product

• 17282-00-7 3-bromo-5-methylpyridin-2-amine 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 107-20-0 2-chloroethanal 

Relevant academic research and scientific papers

Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): Part II

The synthesis of original imidazo[1,2-a]pyridines bearing a thioether side chain at the 3 position and diversely substituted on the 6 or 8 position, and their antiviral activities are reported. From the synthesized compounds, the imidazo[1,2-a]pyridines b

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.

Imidazo[1,2-a]pyridines. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives

A series of 1,2-dihydro-5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinones was synthesized and evaluated for positive inotropic activity. 1,2-Dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3- pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1,2-a]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increase in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1,2-dihydro-5-(6-fluoroimidazo[1,2-a]pyridin-2-yl)-6-methyl-2(1H)- pyridinone (3a) was the most potent (i.v. ED50 11 μg/kg) in this seris. E-1020 is presently under development for the treatment of congestive heart failure.